Format

Send to

Choose Destination
J Invest Dermatol. 2018 Dec;138(12):2606-2616. doi: 10.1016/j.jid.2018.06.168. Epub 2018 Jun 30.

Eosinophils Determine Dermal Thickening and Water Loss in an MC903 Model of Atopic Dermatitis.

Author information

1
Malaghan Institute of Medical Research, Wellington, New Zealand.
2
Division of Pulmonary Medicine, Department of Biochemistry and Molecular Biology, Mayo Clinic, Scottsdale, Arizona, USA.
3
GlycoSyn, Gracefield, Lower Hutt, New Zealand.
4
The Ferrier Research Institute, Victoria University of Wellington, Lower Hutt, New Zealand.
5
The Centenary Institute, Newtown, New South Wales, Australia.
6
The Centenary Institute, Newtown, New South Wales, Australia; Discipline of Dermatology, University of Sydney, Camperdown, New South Wales, Australia; Department of Dermatology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
7
Malaghan Institute of Medical Research, Wellington, New Zealand. Electronic address: elizabeth.forbesblom@rdls.nestle.com.

Abstract

Atopic dermatitis (AD) is a highly debilitating disease with significant health impacts worldwide. It has been a difficult disease to treat because of the wide spectrum of clinical manifestations. Therefore, the current clinical management strategies are nonspecific. Previous studies have documented that AD disease progression is precipitated by a combination of skin barrier dysfunction, itch, and immune dysregulation. However, the precise roles played by effector cells and cytokines have not been fully elucidated. To address this, we established a prolonged model of AD, using MC903. The phenotype of this MC903 model closely resembles the one observed in AD patients, including inflammatory parameters, barrier dysfunction, itch, and histopathological characteristics, thereby providing a platform to evaluate targets for the treatment of AD. This model exposed cells and cytokines that are critically associated with disease severity, including eosinophils, TSLP, and IL-4/IL-13. Indeed, eosinophil depletion significantly ameliorated AD pathology, most notably barrier dysfunction, to a similar extent as blocking of the IL-4/IL-13 axis by genetic deletion of STAT6. Thus, this study has identified eosinophils to be critical for the development and maintenance of AD, thereby proposing these effector cells as therapeutic targets for the treatment of AD.

PMID:
29964034
DOI:
10.1016/j.jid.2018.06.168

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center